Technology
Health
Biotechnology

Rocket Pharmaceuticals

$17.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.40 (2.40%) Today
+$0.40 (2.40%) Today

Why Robinhood?

You can buy or sell RCKT and other stocks, options, ETFs, and crypto commission-free!

About

Rocket Pharmaceuticals, Inc. Common Stock, also called Rocket Pharmaceuticals, is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Read More Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

Employees
39
Headquarters
New York, New York
Founded
Market Cap
752.11M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
279.93K
High Today
$17.30
Low Today
$16.71
Open Price
$16.71
Volume
19.17K
52 Week High
$25.96
52 Week Low
$10.75

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2015 IPO
US

News

MarketBeatMar 7

Stock Price, News, & Analysis for Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under pre...

11
BusinessWireFeb 20

Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City. The fireside chat will take place on Wednesday, February 27, 2019, at 11:00 a.m. Eastern Time. A live audio webcast of the fireside chat will be available on the Invest...

152

Earnings

-$0.66
-$0.56
-$0.47
-$0.37
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.45 per share
Actual
-$0.66 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.